このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Scancell Holdings 将来の成長

Future 基準チェック /06

Scancell Holdings の収益は、年間 13.4% 減少すると予測されています。EPS は、年間減少すると予測されています4.4%。

主要情報

-13.4%

収益成長率

-4.4%

EPS成長率

Biotechs 収益成長	27.3%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	12 Jun 2024

今後の成長に関する最新情報

Recent updates

Is Scancell Holdings (LON:SCLP) A Risky Investment?

Oct 29

Is Scancell Holdings (LON:SCLP) A Risky Investment?

Feb 10

Here's What Scancell Holdings plc's (LON:SCLP) Shareholder Ownership Structure Looks Like

Dec 28

業績と収益の成長予測

AIM:SCLP - アナリストの将来予測と過去の財務データ ( )GBP Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
4/30/2026	N/A	-15	-11	-13	2
4/30/2025	N/A	-14	-11	-11	3
4/30/2024	N/A	-15	-15	-15	3
10/31/2023	N/A	-10	-11	-11	N/A
7/31/2023	3	-11	-9	-9	N/A
4/30/2023	5	-12	-8	-8	N/A
1/31/2023	5	-13	-9	-9	N/A
10/31/2022	5	-13	-11	-10	N/A
7/31/2022	3	-9	-11	-10	N/A
4/30/2022	N/A	-5	-11	-10	N/A
1/31/2022	N/A	-6	-11	-10	N/A
10/31/2021	N/A	-8	-11	-9	N/A
7/31/2021	N/A	-12	-10	-8	N/A
4/30/2021	N/A	-15	-9	-8	N/A
1/31/2021	N/A	-11	-7	-7	N/A
10/31/2020	N/A	-7	-6	-5	N/A
7/31/2020	N/A	-6	-5	-5	N/A
4/30/2020	N/A	-6	-5	-5	N/A
1/31/2020	N/A	-5	-5	-5	N/A
10/31/2019	N/A	-5	-6	-6	N/A
7/31/2019	N/A	-5	-6	-6	N/A
4/30/2019	N/A	-6	-7	-7	N/A
1/31/2019	N/A	-6	-6	-6	N/A
10/31/2018	N/A	-5	-6	-6	N/A
7/31/2018	N/A	-5	-5	-5	N/A
4/30/2018	N/A	-4	-4	-4	N/A
1/31/2018	N/A	-4	-4	-4	N/A
10/31/2017	N/A	-4	-4	-4	N/A
7/31/2017	N/A	-4	N/A	-4	N/A
4/30/2017	N/A	-4	N/A	-4	N/A
1/31/2017	N/A	-3	N/A	-3	N/A
10/31/2016	N/A	-3	N/A	-3	N/A
7/31/2016	N/A	-3	N/A	-3	N/A
4/30/2016	N/A	-3	N/A	-2	N/A
1/31/2016	N/A	-2	N/A	-2	N/A
10/31/2015	N/A	-2	N/A	-3	N/A
7/31/2015	N/A	-2	N/A	-3	N/A
4/30/2015	N/A	-2	N/A	-3	N/A
1/31/2015	N/A	-2	N/A	-2	N/A
10/31/2014	N/A	-2	N/A	-2	N/A
7/31/2014	N/A	-2	N/A	-2	N/A
4/30/2014	N/A	-2	N/A	-2	N/A
1/31/2014	N/A	-2	N/A	-2	N/A
10/31/2013	N/A	-2	N/A	-2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: SCLP今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: SCLP今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: SCLP今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: SCLPの収益がUK市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: SCLP来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: SCLPの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Scancell Holdings 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target decreased by 12% to UK£0.23

Price target increased by 8.6% to UK£0.27

Recent updates

Scancell Holdings plc Appoints Florian Reinaud to the Board

New minor risk - Shareholder dilution

New minor risk - Market cap size

New minor risk - Market cap size

Scancell Holdings plc Appoints Sath Nirmalananthan to the Board

Scancell Holdings plc Directorate and Executive Changes Changes

New minor risk - Share price stability

Scancell Holdings plc to Report First Half, 2024 Results on Jan 30, 2024

Scancell Holdings plc Announces Update on SCOPE Trial

Scancell Holdings plc has completed a Follow-on Equity Offering in the amount of £11.897217 million.

Scancell Holdings plc has filed a Follow-on Equity Offering in the amount of £12.672161 million.

Price target decreased by 12% to UK£0.23

Scancell Holdings plc has filed a Follow-on Equity Offering in the amount of £8.08 million.

New major risk - Negative shareholders equity

Scancell Holdings plc, Annual General Meeting, Nov 29, 2023

Scancell Holdings plc to Report Q4, 2023 Results on Oct 12, 2023

Pharmajet Partner, Scancell, Announces Positive Data from the First Stage of Its Phase 2 Trial of Advanced Melanoma Dna Vaccine Delivered Needle-Free

Scancell Holdings plc Announces Positive Data from the First Stage in its Phase 2 Scope Trial with SCIB1 Cancer Vaccine Delivered by Needle Free Injection for Advanced Melanoma

Scancell Holdings plc Provides an Update on Its Two Ongoing Phase 1/2 Clinical Trials with Lead Cancer Vaccine Assets SCIB1/iSCIB-1+ and Modi-1

Scancell Holdings plc Announces Appointment of Dr Mandeep Sehmi as Head of Business Development

Scancell Appoints Sath Nirmalananthan as CFO

New minor risk - Financial data availability

New minor risk - Market cap size

Scancell Holdings plc Provides an Update on Its Two Ongoing Phase 1/2 Clinical Trials with Lead Cancer Vaccine Assets Scib1/Iscib-1+ and Modi-1

Scancell Holdings plc Provides an Update on Its Two Ongoing Phase 1/2 Clinical Trials with Lead Cancer Vaccine Assets Scib1/Iscib-1+ and Modi-1

Scancell Holdings plc Announces Positive Response in Covidity Trial

Scancell Holdings plc Announces Executive Changes

Price target increased by 8.6% to UK£0.27

Scancell Holdings plc to Report First Half, 2023 Results on Jan 25, 2023

Less than half of directors are independent

Scancell Holdings plc Announces First Patient Dosed in Expansion Phase of Modify

Scancell Holdings plc, Annual General Meeting, Nov 21, 2022

Is Scancell Holdings (LON:SCLP) A Risky Investment?

Scancell Holdings plc Announces Board Changes

Scancell Holdings plc Announces First Patient Dosed in Cohort 2 of the ModiFY Phase 1 Clinical Trial

Scancell Holdings plc to Produce TCB Antibodies

Scancell Holdings plc Announces an Update to the Phase 2 Scope Clinical Trial

Scancell Holdings plc Announces the Enrolment and Treatment of the First Patient in Its Multicentre Modi-1 Clinical Trial (Modify) At Imperial College London, Hammersmith Hospital

Less than half of directors are independent

Scancell Holdings plc Announces Modi-1 Phase 1/2 Trial Open for Recruitment

Scancell Holdings plc Announces Update on Covidity Clinical Trial

Is Scancell Holdings (LON:SCLP) A Risky Investment?

Scancell Holdings plc Announcedsfurther Progress of the Phase 1 Covidity Clinical Trial Being Conducted At the University of Cape Town (UCT) Lung Institute in South Africa

Scancell Holdings plc Announces the UK's Medicines and Healthcare Products Regulatory Authority Approves the Clinical Trial Application to Initiate the First-in-Human Phase I/II Clinical Study of Modi-1

CEO & Director Clifford Holloway has left the company

Scancell Holdings plc Announces COVIDITY Phase 1 Clinical Trial Planned in South Africa and UK for Novel Bivalent COVID-19 Vaccine

New 90-day high: UK£0.21

Scancell Holdings plc Announces an Update on its SCIB2 Clinical Development Partnership with Cancer Research UK

Here's What Scancell Holdings plc's (LON:SCLP) Shareholder Ownership Structure Looks Like

Scancell Holdings plc Appoints Gillies O'Bryan-Tear as Chief Medical Officer and Robert Miller as Medical Director

Scancell Holdings plc to Report Fiscal Year 2020 Results on Oct 16, 2020

Cobra Biologics and Scancell Holdings plc Announces Collaboration to Manufacture COVID-19 Vaccine

Scancell Holdings plc announced that it expects to receive £1.3 million in funding from Cherwell Capital plc, Oxford Technology Management Limited, Oxford Capital Partners LLP, Seneca Partners Limited, Octopus Investments Limited

Scancell Holdings plc has completed a Follow-on Equity Offering in the amount of £9.007417 million.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘